DMC: molecules with a published decision record
197 molecules on this site carry at least one DMC decision. Each page compares that decision with every other agency that assessed the same molecule.
| Molecule | Decisions | Agencies | Class |
|---|---|---|---|
| pembrolizumab | 371 | 15 | Antineoplastics |
| nivolumab | 264 | 15 | Antineoplastics |
| atezolizumab | 120 | 14 | Antineoplastics |
| dupilumab | 116 | 15 | Other dermatologicals |
| daratumumab | 115 | 15 | Antineoplastics |
| olaparib | 114 | 15 | Antineoplastics |
| durvalumab | 108 | 15 | Antineoplastics |
| ibrutinib | 108 | 15 | Antineoplastics |
| upadacitinib | 93 | 16 | Immunosuppressants |
| secukinumab | 79 | 12 | Immunosuppressants |
| budesonide | 76 | 12 | Antidiarrheals / intestinal anti-inflammatories |
| tocilizumab | 76 | 12 | Immunosuppressants |
| ustekinumab | 71 | 11 | Immunosuppressants |
| lenalidomide | 68 | 13 | Immunosuppressants |
| aflibercept | 67 | 11 | Antineoplastics |
| osimertinib | 65 | 14 | Antineoplastics |
| blinatumomab | 64 | 14 | Antineoplastics |
| trastuzumab deruxtecan | 64 | 14 | Antineoplastics |
| venetoclax | 61 | 14 | Antineoplastics |
| tofacitinib | 60 | 13 | Immunosuppressants |
| mepolizumab | 59 | 15 | Obstructive airway diseases |
| zanubrutinib | 58 | 16 | Antineoplastics |
| cabozantinib | 56 | 15 | Antineoplastics |
| guselkumab | 56 | 13 | Immunosuppressants |
| risankizumab | 56 | 14 | Immunosuppressants |
| bimekizumab | 55 | 14 | Immunosuppressants |
| cemiplimab | 55 | 13 | Antineoplastics |
| brentuximab vedotin | 54 | 12 | Antineoplastics |
| ravulizumab | 54 | 15 | Immunosuppressants |
| selpercatinib | 53 | 13 | Antineoplastics |
| acalabrutinib | 52 | 14 | Antineoplastics |
| enzalutamide | 52 | 12 | Endocrine therapy |
| ribociclib | 50 | 14 | Antineoplastics |
| lenvatinib | 49 | 14 | Antineoplastics |
| nintedanib | 49 | 15 | Antineoplastics |
| baricitinib | 48 | 14 | Immunosuppressants |
| tislelizumab | 48 | 12 | Antineoplastics |
| abemaciclib | 47 | 15 | Antineoplastics |
| amivantamab | 47 | 13 | Antineoplastics |
| certolizumab pegol | 43 | 11 | Immunosuppressants |
| omalizumab | 43 | 12 | Obstructive airway diseases |
| avelumab | 42 | 13 | Antineoplastics |
| niraparib | 42 | 15 | Antineoplastics |
| ixekizumab | 41 | 11 | Immunosuppressants |
| ranibizumab | 41 | 10 | Ophthalmologicals |
| dostarlimab | 39 | 14 | Antineoplastics |
| eculizumab | 39 | 11 | Immunosuppressants |
| dabrafenib | 38 | 14 | Antineoplastics |
| darolutamide | 38 | 15 | Endocrine therapy |
| isatuximab | 38 | 12 | Antineoplastics |
| alectinib | 37 | 15 | Antineoplastics |
| obinutuzumab | 37 | 12 | Antineoplastics |
| tisagenlecleucel | 37 | 12 | Antineoplastics |
| emicizumab | 35 | 12 | Antihemorrhagics |
| axicabtagene ciloleucel | 34 | 12 | Antineoplastics |
| burosumab | 34 | 13 | Bone diseases |
| esketamine | 33 | 13 | Psychoanaleptics |
| pegcetacoplan | 33 | 16 | Ophthalmologicals |
| pertuzumab | 32 | 13 | Antineoplastics |
| benralizumab | 31 | 15 | Obstructive airway diseases |
| sacituzumab govitecan | 31 | 15 | Antineoplastics |
| avapritinib | 30 | 11 | Antineoplastics |
| entrectinib | 30 | 13 | Antineoplastics |
| regorafenib | 30 | 12 | Antineoplastics |
| larotrectinib | 29 | 14 | Antineoplastics |
| apalutamide | 28 | 12 | Endocrine therapy |
| encorafenib | 28 | 12 | Antineoplastics |
| letermovir | 28 | 14 | Antivirals |
| ocrelizumab | 28 | 12 | Immunosuppressants |
| tafamidis | 28 | 16 | Other nervous system |
| enfortumab vedotin | 27 | 13 | Antineoplastics |
| lisocabtagene maraleucel | 27 | 11 | Antineoplastics |
| vutrisiran | 27 | 15 | Other nervous system |
| cladribine | 26 | 12 | Immunosuppressants |
| fenfluramine | 26 | 14 | Antiepileptics |
| filgotinib | 26 | 13 | Immunosuppressants |
| glofitamab | 26 | 13 | Antineoplastics |
| lorlatinib | 26 | 12 | Antineoplastics |
| azacitidine | 25 | 11 | Antineoplastics |
| brigatinib | 25 | 14 | Antineoplastics |
| talazoparib | 25 | 13 | Antineoplastics |
| teduglutide | 25 | 12 | Other alimentary tract and metabolism |
| brolucizumab | 24 | 11 | Ophthalmologicals |
| iptacopan | 24 | 12 | Immunosuppressants |
| mirikizumab | 24 | 12 | Immunosuppressants |
| odevixibat | 24 | 13 | Bile and liver therapy |
| ozanimod | 24 | 12 | Immunosuppressants |
| pomalidomide | 24 | 10 | Immunosuppressants |
| tezepelumab | 24 | 13 | Obstructive airway diseases |
| epcoritamab | 23 | 14 | Antineoplastics |
| lanadelumab | 23 | 15 | Other hematological agents |
| polatuzumab vedotin | 23 | 13 | Antineoplastics |
| setmelanotide | 23 | 10 | Antiobesity preparations |
| asciminib | 22 | 15 | Antineoplastics |
| midostaurin | 22 | 11 | Antineoplastics |
| ofatumumab | 22 | 12 | Immunosuppressants |
| selinexor | 22 | 11 | Antineoplastics |
| tipiracil / trifluridine | 22 | 9 | Ophthalmologicals |
| abrocitinib | 21 | 13 | Other dermatologicals |
| belantamab mafodotin | 21 | 10 | Antineoplastics |